Low-molecular-weight heparin use in acute coronary syndromes and percutaneous coronary interventions: An update

Research output: Contribution to journalArticle

Abstract

Based on important studies published in the past year, the role of low-molecular-weight heparin in acute coronary syndromes and percutaneous coronary interventions has continued to evolve. For patients with non-ST-elevation acute coronary syndromes, several alternatives to enoxaparin have been introduced, including fondaparinux and bivalirudin. In patients with ST-elevation myocardial infarction, recent studies have demonstrated a clear mortality benefit from adjunctive antithrombin therapy and the superiority of a prolonged course of enoxaparin over a standard duration of unfractionated heparin. Furthermore, recent data have demonstrated the safety of enoxaparin as an alternative to unfractionated heparin among patients undergoing percutaneous coronary interventions.

Original languageEnglish (US)
Pages (from-to)303-309
Number of pages7
JournalCurrent Cardiovascular Risk Reports
Volume1
Issue number4
DOIs
StatePublished - Dec 1 2007

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Low-molecular-weight heparin use in acute coronary syndromes and percutaneous coronary interventions: An update'. Together they form a unique fingerprint.

  • Cite this